Compare
MBX Biosciences, Inc. vs Zenas BioPharma, Inc. vs Entrada Therapeutics, Inc. vs Akebia Therapeutics, Inc.
| Latest fiscal year | MBX Biosciences, Inc. MBX | Zenas BioPharma, Inc. ZBIO | Entrada Therapeutics, Inc. TRDA | Akebia Therapeutics, Inc. AKBA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $10.00M | $25.42M | $236.20M |
| Revenue growth (YoY) | n/a | +100.0% | -87.9% | +47.5% |
| Gross margin | n/a | n/a | n/a | 83.3% (computed) |
| Operating margin | n/a | n/m | -621.1% | 9.9% |
| Net margin | n/a | n/m | -565.5% | -2.3% |
| Net income | -$86.97M | -$377.74M | -$143.75M | -$5.34M |
| EPS (Diluted) | -$2.38 | -$8.44 | -$3.47 | -$0.02 |
| Operating cash flow | -$79.95M | -$172.33M | -$128.51M | $67.99M |
| Free cash flow | -$81.88M | -$172.35M | -$129.55M | $67.70M |
| Cash & equivalents | $75.29M | $110.64M | $90.39M | $184.84M |
| Total assets | $385.14M | $383.64M | $377.38M | $376.56M |
| Total liabilities | $15.92M | $141.50M | $71.25M | $343.95M |
| Shareholders' equity | $369.22M | $242.14M | $306.13M | $32.61M |
| Return on year-end equity | -23.6% | -156.0% | -47.0% | -16.4% |
| Shares outstanding | 44.93M | 54.49M | 38.28M | 265.42M |
Revenue, most recent five fiscal years
| Fiscal year | MBX Biosciences, Inc. | Zenas BioPharma, Inc. | Entrada Therapeutics, Inc. | Akebia Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $10.00M Ended 2025-12-31 | $25.42M Ended 2025-12-31 | $236.20M Ended 2025-12-31 |
| 1 year earlier | n/a | $5.00M Ended 2024-12-31 | $210.78M Ended 2024-12-31 | $160.18M Ended 2024-12-31 |
| 2 years earlier | n/a | $50.00M Ended 2023-12-31 | $129.01M Ended 2023-12-31 | $194.62M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $292.48M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $211.65M Ended 2021-12-31 |